The PE Ratio as of September 2024 (TTM) for Silence Therapeutics plc (SLN) is -14.08

According to Silence Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -14.08. This represents a change of -56.91% compared to the average of -32.68 of the last 4 quarters.

Silence Therapeutics plc (SLN) Historical PE Ratio (quarterly & annually)

How has SLN PE Ratio performed in the past?

The mean historical PE Ratio of Silence Therapeutics plc over the last ten years is -39.98. The current -14.08 PE Ratio has changed 3.42% with respect to the historical average. Over the past ten years (40 quarters), SLN's PE Ratio was at its highest in in the September 2017 quarter at 43.57. The PE Ratio was at its lowest in in the March 2024 quarter at -101.27.

Silence Therapeutics plc (SLN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Silence Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Silence Therapeutics plc (SLN) Average PE Ratio

How has SLN PE Ratio performed in the past?

The current PE Ratio of Silence Therapeutics plc (SLN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Silence Therapeutics plc (SLN) PE Ratio vs. Peers

How is SLN’s PE Ratio compared to its peers?

Silence Therapeutics plc’s PE Ratio is less than Cidara Therapeutics, Inc. (-0.47), less than Applied Therapeutics, Inc. (-7.15), less than CytomX Therapeutics, Inc. (8.96), less than Shattuck Labs, Inc. (0), less than C4 Therapeutics, Inc. (-2.20), less than Eliem Therapeutics, Inc. (-4.19), less than Prelude Therapeutics Incorporated (-3.91), less than Monte Rosa Therapeutics, Inc. (-1.49), less than Opthea Limited (-3.41), less than Centessa Pharmaceuticals plc (-1.48), less than Nuvalent, Inc. (-11.00), greater than Tarsus Pharmaceuticals, Inc. (-38.43), less than Genfit S.A. (-8.72), less than Avidity Biosciences, Inc. (-4.30), greater than IGM Biosciences, Inc. (-19.34), less than Cerevel Therapeutics Holdings, Inc. (-4.72), greater than Cullinan Oncology, Inc. (-17.73), less than Mineralys Therapeutics, Inc. (-6.95), less than null (-4.99),

Build a custom stock screener for Silence Therapeutics plc (SLN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Silence Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Silence Therapeutics plc (SLN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Silence Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.